GlassScriptPhysician profile
Julie Kramer
NPI 1497219786
$7,517.71
in general payments reported to CMS, 2019-2025
25 companies · $1,412 in 2025
The $1,412 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,395 · 2022: $1,278 · 2023: $1,372 · 2024: $2,061 · 2025: $1,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,743 · Education: $99.99 · Travel and Lodging: $2.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,742.75 |
| Education | $99.99 |
| Travel and Lodging | $2.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,321.45 | 2023-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $1,216.14 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $1,006.23 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $812.38 | 2021-2025 | Winlevi, Absorica Ld |
| Genzyme Corporation | $651.63 | 2021-2025 | |
| Janssen Biotech, INC. | $485.78 | 2021-2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $468.51 | 2021-2025 | |
| Lilly USA, LLC | $219.72 | 2022-2024 | Taltz, Olumiant |
| Dermavant Sciences, INC. | $167.72 | 2023-2024 | Vtama |
| Almirall LLC | $165.86 | 2022-2024 | Seysara, Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $148.04 | 2024 | Cabtreo, Jublia |
| Abbvie INC. | $128.27 | 2021-2024 | |
| Mimedx Group, INC. | $105.21 | 2024-2025 | |
| Leo Pharma INC. | $102.87 | 2025 | Anzupgo, Adbry |
| Galderma Laboratories, L.P. | $99.81 | 2021-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $74.63 | 2023-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $68.56 | 2021-2023 | Libtayo |
| Janssen Scientific Affairs, LLC | $60.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $47.14 | 2021 | |
| Merz North America, INC. | $46.74 | 2021-2023 | Xeomin |
| Journey Medical Corporation | $30.92 | 2022 | |
| Verrica Pharmaceuticals INC. | $27.88 | 2024 | Ycanth |
| Mayne Pharma Commercial LLC | $25.59 | 2022-2023 | |
| Allergan, INC. | $22.17 | 2022 | |
| Dermira, INC. | $14.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.